NCT04065295已完成1 期
A Randomised, Single-blind, Placebo-controlled Trial in Parallel Group Design to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses of BI 1356225 Administered as Oral Solution and Tablets to Healthy Male Subjects, and a Randomised, Open-label, Single-dose, Two-way Cross-over Bioavailability Comparison of BI 1356225 as Tablet With and Without Food
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 65
- 试验地点
- 1
- 主要终点
- The primary endpoint for assessment of safety and tolerability of BI 1356225 is the percentage of subjects with drug-related adverse events (both trial parts)
研究概览
简要总结
The main objectives of the SRD part of this trial are to investigate safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of BI 1356225 in healthy male subjects following oral administration of single rising doses. The main objective of the BA part of this trial will be to explore the influence of food on the bioavailability of tablet fasted versus tablet fed
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single (Participant)
入排标准
- 年龄范围
- 18 Years 至 45 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •Healthy male subjects according to the assessment of the investigator, as based on a complete medical history including a physical examination, vital signs (BP, PR), 12-lead ECG, and clinical laboratory tests
- •Age of 18 to 45 years (inclusive)
- •BMI of 18.5 to 29.9 kg/m2 (inclusive)
- •Signed and dated written informed consent prior to admission to the study, in accordance with GCP and local legislation
排除标准
- •Any finding in the medical examination (including BP, PR or ECG) deviating from normal and assessed as clinically relevant by the investigator
- •Repeated measurement of systolic blood pressure outside the range of 90 to 140 mmHg, diastolic blood pressure outside the range of 50 to 90 mmHg, or pulse rate outside the range of 50 to 90 bpm
- •Any laboratory value outside the reference range that the investigator considers to be of clinical relevance
- •Any evidence of a concomitant disease assessed as clinically relevant by the investigator
- •Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
- •Cholecystectomy or other surgery of the gastrointestinal tract that could interfere with the pharmacokinetics of the trial medication (except appendectomy or simple hernia repair)
- •Diseases of the central nervous system (including but not limited to any kind of seizures or stroke), and other relevant neurological or psychiatric disorders
- •Further exclusion criteria apply
研究组 & 干预措施
Single Rising Dose Part
Experimental
干预措施: BI 1356225 (Drug)
Single Rising Dose Part
Experimental
干预措施: Placebo (Drug)
Bioavailability Part
Experimental
干预措施: BI 1356225 (Drug)
结局指标
主要结局
The primary endpoint for assessment of safety and tolerability of BI 1356225 is the percentage of subjects with drug-related adverse events (both trial parts)
时间窗: Up to 30 days
次要结局
- AUC0-∞ (area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity)(Up to 30 days)
- Cmax (maximum measured concentration of the analyte in plasma)(Up to 30 days)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
A Study in Healthy Men to Test How the Body Takes up and Tolerates Different Doses of BI 474121, and Whether it Makes a Difference if BI 474121 is Taken as a Tablet or a Drink.HealthyNCT04194645Boehringer Ingelheim66
已完成
1 期
A Study in Healthy Men to Test How Well Different Doses of BI 3802876 Are ToleratedHealthyNCT06081530Boehringer Ingelheim59
已完成
1 期
A Study in Healthy Men to Test How Well Different Doses of BI 3731579 Are ToleratedHealthyNCT06429137Boehringer Ingelheim63
已完成
1 期
A Study to Test How Well Different Doses of BI 765845 Are Tolerated by Healthy PeopleHealthyNCT06139315Boehringer Ingelheim92
已完成
1 期
IAMA-6 Oral Dose Study in Healthy AdultsNeurodevelopmental DisordersNCT06300398Iama Therapeutics S.r.l.72